Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study

BACKGROUND: Migraine is associated with depression as well as negative impact on quality of life and work productivity. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa), selectively targets the calcitonin gene‐related peptide and has proven efficacy for the preventive treatment of migrai...

Descripción completa

Detalles Bibliográficos
Autores principales: Spierings, Egilius L. H., Ning, Xiaoping, Ramirez Campos, Verena, Cohen, Joshua M., Barash, Steve, Buse, Dawn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597120/
https://www.ncbi.nlm.nih.gov/pubmed/34374086
http://dx.doi.org/10.1111/head.14196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597120/
https://www.ncbi.nlm.nih.gov/pubmed/34374086
http://dx.doi.org/10.1111/head.14196

Ejemplares similares